Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). - Wikidata - wikimedia - TriplyDB

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

http://www.wikidata.org/entity/Q37331296

about

Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis You're only as old as your arteries: translational strategies for preserving vascular endothelial function with aging Targeting inflammation in diabetes: Newer therapeutic options The obesity-induced transcriptional regulator TRIP-Br2 mediates visceral fat endoplasmic reticulum stress-induced inflammation Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor κB.LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.Comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139 Why do statins reduce cardiovascular disease more than other lipid modulating therapies?Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin.Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTB4 are pro-inflammatory molecules that can be targeted to restore insulin sensitivity.Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus.Krüppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease.

P2860

Q26746659-6B0BD30C-3225-4376-A89C-A7035BB4E34C Q26824357-29FFEF24-4893-41C6-AB8E-C88CDD767DF9 Q26852726-714C98A5-BDE7-449C-B842-78C3B56739CD Q28834050-FEF5661F-655F-496D-876A-ECF405A7E50D Q34444895-71BCD35B-93E3-463E-A813-EF7044D2CF97 Q35122399-38C213A6-93B5-411A-96E8-ECA37E6AF665 Q35534914-314223B3-A4DF-4343-A270-6827AC7CC967 Q35600641-1520A9FD-155B-42E0-BABC-D57991997B90 Q36926364-AF4726C3-3415-4B11-8A6F-E9741EC413FC Q36926367-0686C257-8BBD-41B8-805D-B7F2BB5153C4 Q38253965-B17AEB2C-8BDA-4DF8-8439-FDA876A1094C Q38741861-1F024290-E5DB-40B6-8BBF-6AD9EE2E2C9C Q38747825-5A38D11F-B3F4-404E-A365-5CA8BE19B6C1 Q38845570-AA69E9BA-0A0A-4329-BBFA-7B3EC6EC9E66 Q50233845-B4CA61D2-D610-4513-9BAC-4FEBB496A4CA Q53137711-8D32DD21-903A-41BC-91E7-E568560AB5D7 Q53785378-039D5574-9284-45E3-A9A3-CE9F29BEEDE0 Q55250888-92DE5406-3473-4770-9E25-9AD4D3B5CCC5

P2860

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

http://www.wikidata.org/entity/Q37331296

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting inflammation using s ...... ediated dilation (TINSAL-FMD).

@en

Targeting inflammation using s ...... ects on flow-mediated dilation

@nl

type

label

Targeting inflammation using s ...... ediated dilation (TINSAL-FMD).

@en

Targeting inflammation using s ...... ects on flow-mediated dilation

@nl

prefLabel

Targeting inflammation using s ...... ediated dilation (TINSAL-FMD).

@en

Targeting inflammation using s ...... ects on flow-mediated dilation

@nl

P1433

Q37331296-6C1B270A-A78C-4972-A99B-9554703251BB

P1476

Q37331296-8F1F4426-7AB6-464C-8DF4-E2B86EE40F6A

P2093

Q37331296-3AD96392-12A2-489E-BFC6-73D7625DBDB4

Q37331296-3BFFB7D5-51B0-432E-A376-C949D5EAD262

Q37331296-3DE56D3E-1297-48FA-B8A1-36A468093206

Q37331296-61AABF1C-205D-499C-AFBF-9C04751B4702

Q37331296-7C6D5827-CEEE-4D63-B5C4-4BB4E19332F4

Q37331296-7D386245-3E8B-4B12-BECB-957B04ED9814

Q37331296-9CCECA09-BDD1-4D25-B2CE-92B06287A739

Q37331296-B2337F7B-F96C-460B-BCB1-25E44F5BA29A

Q37331296-E0C3E2D5-FD29-479B-AB36-D3F2A1FC8277

P2860

Q37331296-0AF78016-562D-4FB8-8494-763BF956AF91

Q37331296-0B66D67C-E456-4ABF-BBEF-2FBDF9D89E93

Q37331296-0E15FF20-01F0-43D5-99F9-F55FABE72AE9

Q37331296-169B2B83-5DA1-4735-89DF-EEA49493A0CF

Q37331296-20A7D526-9575-4FB9-956E-B8B2C1757D6F

Q37331296-24E8B44A-A938-4844-8A6C-4AEF46424094

Q37331296-2695EF09-31DA-4E74-AF05-3E3801FC4D61

Q37331296-2C4406D5-AE25-4433-B593-D5C53283B844

Q37331296-32BB46EB-6BF7-4F9D-AC76-4DB15A9B073C

Q37331296-3AF4BE50-7ACB-422B-9479-C40E5F18F0D9

P304

Q37331296-E14B881E-6802-40BF-BF25-EF29C24E5F87

P31

Q37331296-95CE9557-D9BA-4B6F-ACEF-DC7DC5455380

P356

Q37331296-797FB92F-F8A2-4E3C-947C-62C615812A9F

P407

Q37331296-BF13173C-7389-456C-8715-43FF952C0687

P433

Q37331296-4B45D4DA-84F9-4B7C-95F1-73D3FF28B475

P478

Q37331296-78DDD12F-3C7A-437F-971C-C4C70A9987F2

P577

Q37331296-840F807F-0E04-4B6C-9A3B-0283F4E96227

P5875

Q37331296-E0267A96-4906-4AC9-97B4-79A00767A628

P698

Q37331296-6D08742C-50A3-4F6E-8D41-9A0A871F4DF3

P921

Q37331296-74013F3A-EB9D-403A-8839-6EC9015A8221

Q37331296-A40CD143-9318-4ED7-B73F-33ECC073606B

Q37331296-AD2B199C-E42C-41FE-911D-E7E0DFE27C0B

P932

Q37331296-03FD4DAB-EA4D-4750-B465-38D2EF211044

P356

P1433

P1476

Targeting inflammation using s ...... ediated dilation (TINSAL-FMD).

@en

P2093

Allison B Goldfine

http://www.w3.org/2001/XMLSchema#string

Cyrus Desouza

http://www.w3.org/2001/XMLSchema#string

J Stewart Buck

http://www.w3.org/2001/XMLSchema#string

Kathleen A Jablonski

http://www.w3.org/2001/XMLSchema#string

Mark A Creager

http://www.w3.org/2001/XMLSchema#string

Steven E Shoelson

http://www.w3.org/2001/XMLSchema#string

TINSAL-FMD (Targeting Inflamma ...... Dilation) Ancillary Study Team

http://www.w3.org/2001/XMLSchema#string

Vivian Fonseca

http://www.w3.org/2001/XMLSchema#string

Yii-Der Ida Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

The ancient drug salicylate directly activates AMP-activated protein kinase

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases

Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization

Inflammation in atherosclerosis

Inhibition of NF-kappa B by sodium salicylate and aspirin

Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis

P304

4132-4139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0859

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257839512

http://www.w3.org/2001/XMLSchema#string

P698

24130358

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3836144

http://www.w3.org/2001/XMLSchema#string